Your browser doesn't support javascript.
loading
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause, B L; Sznol, M; Kopp, W C; Janik, J E; Smith, J W; Steis, R G; Urba, W J; Sharfman, W; Fenton, R G; Creekmore, S P; Holmlund, J; Conlon, K C; VanderMolen, L A; Longo, D L.
Afiliación
  • Gause BL; Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, USA. bgause@mail.ncifcrf.gov
J Clin Oncol ; 14(8): 2234-41, 1996 Aug.
Article en En | MEDLINE | ID: mdl-8708712
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Interleucina-2 / Interferón-alfa / Neoplasias / Antineoplásicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 1996 Tipo del documento: Article País de afiliación: Estados Unidos
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Interleucina-2 / Interferón-alfa / Neoplasias / Antineoplásicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 1996 Tipo del documento: Article País de afiliación: Estados Unidos